1. Background
2. Methods
2.1. In Silico Prediction
2.1.1. Data set
2.2. Anticp Tool
2.3. Peptides Preparation
2.4. Culture Medium and Cell Lines
2.5. Cytotoxicity Assay
2.6. Statistical Analysis
3. Results
3.1. Anticp Analysis
| Peptide ID | Sequence ID | Peptide Sequence | SVM | Prediction |
|---|---|---|---|---|
| P1 | 1 - 20 | MKLVFLVLLFLGALGLCLAG | 0.81 | Non-Anticp |
| P2 | 10 - 30 | LGALGLCLAGRRRRSVQWCA | 0.71 | Non-Anticp |
| P3 | 20 - 40 | RRRRSVQWCAVSQPEATKCF | 0.71 | Non-Anticp |
| P4 | 30 - 50 | VSQPEATKCFQWQRNMRKVR | 0.83 | Non-Anticp |
| P5 | 40 - 60 | QWQRNMRKVRGPPVSCIKRD | 0.63 | Non-Anticp |
| P6 | 50 - 70 | GPPVSCIKRDSPIQCIQAIA | 0.44 | Non-Anticp |
| P7 | 60 - 80 | SPIQCIQAIAENRADAVTLD | 0.87 | Non-Anticp |
| P8 | 70 - 90 | ENRADAVTLDGGFIYEAGLA | 0.72 | Non-Anticp |
| P9 | 80 - 100 | GGFIYEAGLAPYKLRPVAAE | 0.54 | Non-Anticp |
| P10 | 90 - 110 | PYKLRPVAAEVYGTERQPRT | 0.76 | Non-Anticp |
| P11 | 100 - 120 | VYGTERQPRTHYYAVAVVKK | 0.83 | Non-Anticp |
| P12 | 110 - 130 | HYYAVAVVKKGGSFQLNELQ | 0.78 | Non-Anticp |
| P13 | 120 - 140 | GGSFQLNELQGLKSCHTGLR | 0.55 | Non-Anticp |
| P14 | 130 - 150 | GLKSCHTGLRRTAGWNVPIG | 0.46 | Non-Anticp |
| P15 | 140 - 160 | RTAGWNVPIGTLRPFLNWTG | 0.67 | Non-Anticp |
| P16 | 150 - 170 | TLRPFLNWTGPPEPIEAAVA | 0.54 | Non-Anticp |
| P17 | 160 - 180 | PPEPIEAAVARFFSASCVPG | 0.90 | Non-Anticp |
| P18 | 170 - 190 | RFFSASCVPGADKGQFPNLC | 0.60 | Non-Anticp |
| P19 | 180 - 200 | ADKGQFPNLCRLCAGTGENK | 0.67 | Non-Anticp |
| P20 | 190 - 210 | RLCAGTGENKCAFSSQEPYF | 0.88 | Non-Anticp |
| P21 | 200 - 220 | CAFSSQEPYFSYSGAFKCLR | 0.70 | Non-Anticp |
| P22 | 210 - 230 | SYSGAFKCLRDGAGDVAFIR | 0.71 | Non-Anticp |
| P23 | 220 - 240 | DGAGDVAFIRESTVFEDLSD | 0.76 | Non-Anticp |
| P24 | 230 - 250 | ESTVFEDLSDEAERDEYELL | 0.90 | Anticp |
| P25 | 240 - 260 | EAERDEYELLCPDNTRKPVD | 0.75 | Non-Anticp |
| P26 | 250 - 270 | CPDNTRKPVDKFKDCHLARV | 0.75 | Non-Anticp |
| P27 | 260 - 280 | KFKDCHLARVPSHAVVARSV | 0.79 | Non-Anticp |
| P28 | 270 - 290 | PSHAVVARSVNGKEDAIWNL | 0.80 | Non-Anticp |
| P29 | 280 - 300 | NGKEDAIWNLLRQAQEKFGK | 0.60 | Non-Anticp |
| P30 | 290 - 310 | LRQAQEKFGKDKSPKFQLFG | 0.85 | Non-Anticp |
| P31 | 300 - 320 | DKSPKFQLFGSPSGQKDLLF | 0.61 | Non-Anticp |
| P32 | 310 - 330 | SPSGQKDLLFKDSAIGFSRV | 0.78 | Non-Anticp |
| P33 | 320 - 340 | KDSAIGFSRVPPRIDSGLYL | 0.89 | Non-Anticp |
| P34 | 330 - 350 | PPRIDSGLYLGSGYFTAIQN | 0.71 | Non-Anticp |
| P35 | 340 - 360 | GSGYFTAIQNLRKSEEEVAA | 0.51 | Non-Anticp |
| P36 | 350 - 370 | LRKSEEEVAARRARVVWCAV | 0.82 | Non-Anticp |
| P37 | 360 - 380 | RRARVVWCAVGEQELRKCNQ | 0.69 | Non-Anticp |
| P38 | 370 - 390 | GEQELRKCNQWSGLSEGSVT | 0.42 | Non-Anticp |
| P39 | 380 - 400 | WSGLSEGSVTCSSASTTEDC | 0.94 | Anticp |
| P40 | 390 - 410 | CSSASTTEDCIALVLKGEAD | 0.94 | Anticp |
| P41 | 400 - 420 | IALVLKGEADAMSLDEGYVY | 0.85 | Non-Anticp |
| P42 | 410 - 430 | AMSLDEGYVYTAGKCGLVPV | 0.87 | Non-Anticp |
| P43 | 420 - 440 | TAGKCGLVPVLAENYKSQQS | 0.87 | Non-Anticp |
| P44 | 430 - 450 | LAENYKSQQSSDPDPNCVDR | 0.73 | Non-Anticp |
| P45 | 440 - 460 | SDPDPNCVDRPVEGYLAVAV | 0.85 | Non-Anticp |
| P46 | 450 - 470 | PVEGYLAVAVVRRSDTSLTW | 0.59 | Non-Anticp |
| P47 | 460 - 480 | VRRSDTSLTWNSVKGKKSCH | 0.72 | Non-Anticp |
| P48 | 470 - 490 | NSVKGKKSCHTAVDRTAGWN | 0.81 | Non-Anticp |
| P49 | 480 - 500 | TAVDRTAGWNIPMGLLFNQT | 0.74 | Non-Anticp |
| P50 | 490 - 510 | IPMGLLFNQTGSCKFDEYFS | 0.73 | Non-Anticp |
| P51 | 500 - 520 | GSCKFDEYFSQSCAPGSDPR | 0.50 | Non-Anticp |
| P52 | 510 - 530 | QSCAPGSDPRSNLCALCIGD | 0.80 | Non-Anticp |
| P53 | 520 - 540 | SNLCALCIGDEQGENKCVPN | 0.73 | Non-Anticp |
| P54 | 530 - 550 | EQGENKCVPNSNERYYGYTG | 0.81 | Non-Anticp |
| P55 | 540 - 560 | SNERYYGYTGAFRCLAENAG | 0.52 | Non-Anticp |
| P56 | 550 - 570 | AFRCLAENAGDVAFVKDVTV | 0.52 | Non-Anticp |
| P57 | 560 - 580 | DVAFVKDVTVLQNTDGNNNE | 0.72 | Non-Anticp |
| P58 | 570 - 590 | LQNTDGNNNEAWAKDLKLAD | 0.60 | Non-Anticp |
| P59 | 580 - 600 | AWAKDLKLADFALLCLDGKR | 0.66 | Non-Anticp |
| P60 | 590 - 610 | FALLCLDGKRKPVTEARSCH | 0.89 | Non-Anticp |
| P61 | 600 - 620 | KPVTEARSCHLAMAPNHAVV | 0.82 | Non-Anticp |
| P62 | 610 - 630 | LAMAPNHAVVSRMDKVERLK | 0.82 | Non-Anticp |
| P63 | 620 - 640 | SRMDKVERLKQVLLHQQAKF | 0.80 | Non-Anticp |
| P64 | 630 - 650 | QVLLHQQAKFGRNGSDCPDK | 0.75 | Non-Anticp |
| P65 | 640 - 660 | GRNGSDCPDKFCLFQSETKN | 0.43 | Non-Anticp |
| P66 | 650 - 670 | FCLFQSETKNLLFNDNTECL | 0.90 | Anticp |
| P67 | 660 - 680 | LLFNDNTECLARLHGKTTYE | 0.88 | Non-Anticp |
| P68 | 670 - 690 | ARLHGKTTYEKYLGPQYVAG | 0.78 | Non-Anticp |
| P69 | 680 - 700 | KYLGPQYVAGITNLKKCSTS | 0.55 | Non-Anticp |
| P70 | 690 - 710 | ITNLKKCSTSPLLEACEFLR | 0.82 | Non-Anticp |
3.2. Cytotoxicity Assay
Cytotoxic activity of P39, P40, and P38 peptides against MDA-MB-231, MCF-7, and HEK cell lines. Cells were treated with different concentrations of the peptides for 72 hr. The effect was measured by MTT cell viability assay. The results are presented as means ± SD of three independent experiments. ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05 compared with non-anticancer peptide P38.
